Dublin, Feb. 09, 2017 -- Research and Markets has announced the addition of the "Norovirus Forecast for selected Asian Markets 2017-2027" report to their offering.
Currently, there are six recognized norovirus genogroups, three of which (GI, GII, and GIV) affect humans. More than 25 different genotypes have been identified within these three genogroups. Variants of the GII.4 genotype are the most common cause of norovirus outbreaks.
This report provides the current incident population for Norovirus across Selected Asian Markets (Cambodia, Indonesia, Lao PDR and Vietnam) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms of Norovirus have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Signs and symptoms of norovirus infection include:
- Nausea
- Vomiting
- Abdominal pain or cramps
- Watery or loose diarrhoea
- Malaise
- Low-grade fever
- Muscle pain
Reasons to Buy:
- Able to quantify patient populations in global Norovirus's market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the incidence of the subdivided types of Norovirus and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Identify sub-populations within Norovirus which require treatment.
- Gain an understanding of the specific markets that have the largest number of Norovirus patients.
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Methodology for quantification of patient numbers
8. Top-line Estimated Incidence for Norovirus
9. Norovirus in Vietnam
10. Abbreviations used in the report
11. Patient-Based Offering
12. Online Pricing Data and Platforms
13. References
14. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/q7lfn6/norovirus
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Gastrointestinal Drugs


Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
OpenAI Addresses Security Vulnerability in macOS App Certification Process
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 



